ArticleScientific reports2025
'Bioinspired nano-architected chitosan-β-glucan nanocomposite as an elicitor for disease management sustainably'.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development and utilization of innovative nano-biomaterials have ushered in a paradigm shift in sustainable disease management and immune modulation. Their application is crucial in combating the soil-born pathogen Sclerotium rolfsii, which impacts over 500 crops, causing substantial global economic losses. Present work reports a groundbreaking innovative development strategy of nanoengineering of chitosan-yeast β-glucan (C-YB) as well as chitosan-S. rolfsii β-glucan (C-SB) composites to bio-mimic Microbe/Pathogen-Associated Molecular Patterns (M/PAMPs) for synergistic immune stimulation while countering immune suppression induced by pathogen. The eco-friendly, microwave-based synthesized nanocomposites exhibit remarkable antifungal properties and feature an amorphous structure with spherical shapes measuring 96.81 nm for C-YB and 98.66 nm for C-SB. These nanocomposites completely suppress S. rolfsii at concentrations as low as 220 ppm for C-YB and 240 ppm for C-SB, significantly outperforming chitosan nanoparticles (600 ppm) and chemical fungicides (2000 ppm). Further, this study highlights the modulation of enzymatic activity and chitinase and β-glucanase enzyme secretion by S. rolfsii which is the first report, offering new insights into its enzymatic dynamics. Exploring the antifungal mechanism of action, microscopic observation reveals that these synthesized nanomaterials induce malformations and cellular disorganization in S. rolfsii, culminating in growth inhibition and cell death. This strategic framework introduces innovative bioengineered nanocomposites with aims to enhance resilience by orchestrating a series of immune responses to various stresses in sugarbeet. These advancements not only contribute to the bio-circular economy but also hold promising potential for versatile applications across agriculture, pharmaceuticals, medical and industrial fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.